Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

The Tarrytown, New York-based company said it had profit of $12.81 per share. Earnings, adjusted for one-time gains and costs, were $12.89 per share. The results exceeded Wall Street expectations. The ...

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...

U.S. sales of EYLEA HD and EYLEA, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...

Earnings season begins this week. With the tariff overhang and higher expectations for coming quarters, forward earnings guidance from management will be crucial.

26 analysts have shared their evaluations of Regeneron Pharmaceuticals REGN during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Hexcel (HXL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good ...

Wall Street expects a year-over-year decline in earnings on higher revenues when United Airlines (UAL) reports results for the quarter ended June 2025. While this widely-known consensus outlook is ...